Astria Therapeutics, Inc. has announced that it will present new clinical data at the 2025 US Hereditary Angioedema Association National Summit. The company is set to present four posters, showcasing various aspects of its ongoing research. Timothy Craig, D.O., will provide an encore presentation on the global Phase 3 trial of navenibart in hereditary angioedema patients. Michael E. Manning, M.D., will present initial safety and efficacy data from the Phase 1b/2 and long-term open-label trials. Mindy DeMarco, RN, will address recruitment challenges in rare disease trials, while H. Henry Li, M.D., will discuss interim results on attack severity reduction from the ALPHA-STAR trial. The results will be presented during the summit, taking place from July 10-13, 2025, in Baltimore, Maryland.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。